J. Lipid Res. Please sign the JLR Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M700076-JLR200 on June 11, 2007

Papers In Press, published online ahead of print September 1, 2007
J. Lipid Res., doi:10.1194/jlr.M700076-JLR200
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
M700076-JLR200v1
48/9/2072    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singer, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singer, J. B.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 48, 2072-2078, September 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Patient-Oriented and Epidemiological Research

Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipientsboxs

Jonathan B. Singer1,*, Hallvard Holdaas{dagger}, Alan G. Jardine§, Bengt Fellstrøm**, Ingrid Os{dagger}{dagger}, Georgina Bermann§§, Joanne M. Meyer* on behalf of the Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators

* Clinical Pharmacogenetics, Novartis Institutes for Biomedical Research, Cambridge, MA
{dagger} Medical Department, Rikshospitalet, Oslo, Norway
§ Department of Medicine and Therapeutics, University of Glasgow, Glasgow, United Kingdom
** University Hospital, Uppsala, Sweden
{dagger}{dagger} School of Medicine, University of Oslo, Oslo, Norway
§§ Biostatistics and Statistical Reporting, Novartis Pharma AG, Basel, Switzerland

boxs The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of one table.

Published, JLR Papers in Press, June 11, 2007.

1 To whom correspondence should be addressed. e-mail: jonathan.singer{at}novartis.com


ABSTRACT

The Assessment of Lescol in Renal Transplantation clinical trial demonstrated the efficacy of fluvastatin in reducing cardiovascular (CV) disease in renal transplant recipients. The study included a voluntary pharmacogenetic component, enrolling 1,404 patients, which allowed association testing of baseline measures and longitudinal analysis of the 707 fluvastatin-treated and 697 placebo-treated individuals. A candidate gene approach, examining 42 polymorphisms in 18 genes, was used to test for association between selected polymorphisms and major adverse cardiac events, graft failure, change in LDL and HDL cholesterol, and baseline LDL and HDL cholesterol. Reported associations between cholesteryl ester transfer protein (CETP) and baseline HDL cholesterol were replicated, with four previously implicated single nucleotide polymorphisms significantly associated in males and one in females; tests of reported associations between CETP and CV disease yielded varying results. We found no evidence for genetic factors affecting fluvastatin response. Polymorphisms in 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) previously reported to affect the efficacy of pravastatin did not show a similar effect on the reduction of LDL cholesterol by fluvastatin.

Supplementary key words pharmacogenetics • association • cholesteryl ester transfer protein • 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Abbreviations: ALERT, Assessment of Lescol in Renal Transplantation; CETP, cholesteryl ester transfer protein; CV, cardiovascular; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; MACE, major adverse cardiac events; MI, myocardial infarction; PRINCE, Pravastatin Inflammation/CRP Evaluation; RTR, renal transplant recipient; SNP, single nucleotide polymorphism


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.